Debio-4127 by Debiopharm International for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData, Phase II drugs for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData's report assesses how Debio-4127's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.Debio-4127 overviewDebio-4127 is under development for the treatment of gastroenteropancreatic neuroendocrine tumor. The drug candidate is a long acting octreotide and acts by targeting somatostatin receptor (SSTR). It is administered through parenteral route of administration.Debiopharm International overviewDebiopharm International, a subsidiary of Debiopharm Group, focuses on the development and manufacture of drugs for oncology and bacterial infections. The company offers oxaliplatin and triptorelin drugs. It is investigating proteins, peptides and small molecules to treat cancers, solid tumors, bone and joint infections and gastrointestinal disorders. Debiopharm is headquartered in Lausanne, Switzerland. For a complete picture of Debio-4127's drug-specific PTSR and LoA scores, buy the report here.
Debio-4127 is under clinical development by Debiopharm International and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
What's Your Reaction?
